Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Other Non-Current Liabilities (2017)

Viking Therapeutics' Other Non-Current Liabilities history spans 3 years, with the latest figure at $47113.0 for Q1 2017.

  • For Q1 2017, Other Non-Current Liabilities fell 76.78% year-over-year to $47113.0; the TTM value through Mar 2017 reached $47113.0, down 76.78%, while the annual FY2015 figure was $183611.0, N/A changed from the prior year.
  • Other Non-Current Liabilities for Q1 2017 was $47113.0 at Viking Therapeutics, down from $202882.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $202882.0 in Q1 2016 and bottomed at $47113.0 in Q1 2017.
  • The 3-year median for Other Non-Current Liabilities is $183611.0 (2015), against an average of $144535.3.
  • The largest YoY upside for Other Non-Current Liabilities was 76.78% in 2017 against a maximum downside of 76.78% in 2017.
  • A 3-year view of Other Non-Current Liabilities shows it stood at $183611.0 in 2015, then increased by 10.5% to $202882.0 in 2016, then plummeted by 76.78% to $47113.0 in 2017.
  • Per Business Quant, the three most recent readings for VKTX's Other Non-Current Liabilities are $47113.0 (Q1 2017), $202882.0 (Q1 2016), and $183611.0 (Q4 2015).